Aethlon Medical Publishes Long COVID Study Findings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Source: PRnewswire
- Research Advancement: Aethlon Medical's preclinical study published on November 20, 2025, indicates that elevated extracellular vesicles in Long COVID plasma may provide a therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin, suggesting potential breakthroughs in Long COVID treatment.
- Clinical Collaboration: The study, conducted in partnership with the UCSF Long COVID clinic, analyzed plasma samples from Long COVID patients and recovered controls, revealing significantly higher levels of extracellular vesicles in Long COVID patients, highlighting the device's potential application in treating post-COVID symptoms.
- Technological Innovation: The Hemopurifier® device effectively removes harmful extracellular vesicles through plasma separation and GNA affinity resin, previously demonstrated in severe acute COVID-19 patients, indicating its potential efficacy in Long COVID patients and expanding its clinical application scope.
- Market Potential: With Long COVID affecting 44 to 48 million people in the U.S. and an estimated economic burden of $2 billion, Aethlon's research findings could introduce new treatment options in this area, enhancing the company's competitiveness in the medical device market.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like AEMD with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on AEMD
About AEMD
Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aethlon Medical Secures $3.3 Million Financing to Accelerate Cancer Treatment
- Financing Agreement: Aethlon Medical has entered into a securities purchase agreement with a single institutional investor to sell 595,897 shares and warrants for 1,042,820 shares, raising approximately $3.3 million, expected to close on December 8, 2025, enhancing liquidity for R&D support.
- Warrant Inducement: The company has negotiated a warrant inducement agreement to lower the exercise price of March and September 2025 warrants to $4.03, which is expected to encourage the investor to exercise these warrants, providing additional funding for the company.
- Market Compliance: This financing adheres to Nasdaq rules under Section 4(a)(2) of the Securities Act, ensuring the company's compliance in capital markets, which enhances investor confidence and improves the company's reputation.
- Future Growth Potential: Aethlon is focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases, and this financing will accelerate clinical trial processes, boosting the company's competitiveness in the medical device sector.
Continue Reading
American Eagle Shares Rise 15%; Check Out 20 Stocks Making Moves in Premarket Trading
American Eagle Outfitters Performance: American Eagle Outfitters Inc. reported third-quarter revenue of $1.36 billion and adjusted earnings of 53 cents per share, both exceeding analyst expectations, leading to a 14.8% increase in share price during pre-market trading.
Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including Powell Max Ltd (up 70%), Creative Media & Community Trust Corp (up 53.3%), and SMX (up 27.3%).
Significant Losers: Lulu’s Fashion Lounge Holdings Inc. experienced a dramatic drop of 58.3%, while ScanTech AI Systems Inc. fell 35.8% after receiving a delisting determination from Nasdaq.
Market Reactions: The overall market showed mixed reactions with various companies reporting earnings and guidance updates, impacting their stock prices significantly in pre-market trading.
Continue Reading